Literature DB >> 6301931

Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol.

W M Davis, N S Hatoum.   

Abstract

1. Neither cannabichromene (CBC) nor delta 9-tetrahydrocannabinol (THC) protected mice from electroshock-induced seizures, although THC inhibited postictal mortality. Minor effects were produced on seizure latency and duration. 2. CBC had a weak analgetic action in mice; THC had a moderate and lengthy effect, which was potentiated at 2 hr by concurrent CBC. 3. Both CBC (10-75 mg/kg, i.p.) and THC (20 mg/kg) reduced motility of mice, the THC equalling the highest dose of CBC. 4. Performance of a conditioned avoidance response was strongly impaired by THC, but not by CBC, nor did CBC combined with THC have influence on the effects of THC.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301931     DOI: 10.1016/0306-3623(83)90004-6

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  15 in total

1.  Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Authors:  Angelo A Izzo; Raffaele Capasso; Gabriella Aviello; Francesca Borrelli; Barbara Romano; Fabiana Piscitelli; Laura Gallo; Francesco Capasso; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Cannabichromene is a cannabinoid CB2 receptor agonist.

Authors:  Michael Udoh; Marina Santiago; Steven Devenish; Iain S McGregor; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-11-21       Impact factor: 8.739

Review 3.  Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Authors:  Ethan B Russo
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.

Authors:  Gerald T DeLong; Carl E Wolf; Alphonse Poklis; Aron H Lichtman
Journal:  Drug Alcohol Depend       Date:  2010-11-01       Impact factor: 4.492

Review 5.  Differentiating Cannabis Products: Drugs, Food, and Supplements.

Authors:  Arash Salehi; Keely Puchalski; Yalda Shokoohinia; Behzad Zolfaghari; Sedigheh Asgary
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

Review 6.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

Review 7.  Cannabis sativa: The Plant of the Thousand and One Molecules.

Authors:  Christelle M Andre; Jean-Francois Hausman; Gea Guerriero
Journal:  Front Plant Sci       Date:  2016-02-04       Impact factor: 5.753

Review 8.  Designing microorganisms for heterologous biosynthesis of cannabinoids.

Authors:  Ângela Carvalho; Esben Halkjær Hansen; Oliver Kayser; Simon Carlsen; Felix Stehle
Journal:  FEMS Yeast Res       Date:  2017-06-01       Impact factor: 2.796

9.  Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots.

Authors:  Dan Jin; Philippe Henry; Jacqueline Shan; Jie Chen
Journal:  Front Plant Sci       Date:  2021-07-01       Impact factor: 5.753

10.  Cannabinoids in the management of difficult to treat pain.

Authors:  Ethan B Russo
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.